Clinical study indicates that cannabidiol may reduce blood pressure in hypertensive patients

A clinical study published on the PubMed website investigated the effects of cannabidiol (CBD) on blood pressure in individuals with mild to moderate hypertension. The research evaluated the oral and continuous use of the substance and observed relevant reductions in pressure levels throughout the day, measured by 24-hour ambulatory monitoring.

Methodology and results

The study involved 70 participants and used a randomized, triple-blind, placebo-controlled crossover design. Volunteers received CBD for five weeks and, in another period, placebo, allowing for a direct comparison of effects.

The results showed a reduction in the average 24-hour blood pressure, including decreases in systolic and diastolic pressures, even among participants already taking antihypertensive medications. The effects began to be observed after about two and a half weeks of treatment.

Safety and next steps

According to the authors, cannabidiol was well tolerated, with no serious adverse events or significant clinical changes, reinforcing its safety potential in the evaluated protocol. Despite the positive findings, the study highlights the need for larger and longer-term research to confirm the benefits and define the role of CBD as a complementary therapy in hypertension control.